Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Hurricane Maria Continues to Wreak Havoc on the Medical Industry

Though it has been nearly four months since Hurricane Maria made landfall in Puerto Rico, the effects continue to devastate the medical industry both on the island and the mainland. The power grid on the island remains mostly inoperable, leaving Puerto Rico’s many medical equipment manufacturing plants unable to operate. The United States Food and…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Though it has been nearly four months since Hurricane Maria made landfall in Puerto Rico, the effects continue to devastate the medical industry both on the island and the mainland. The power grid on the island remains mostly inoperable, leaving Puerto Rico’s many medical equipment manufacturing plants unable to operate.

The United States Food and Drug Administration (FDA) has confirmed that the U.S. territory of Puerto Rico typically produces about $40 billion worth of pharmaceuticals each year. This amounts to more pharmaceutical production than any one of the 50 states, any other U.S. territory, or any single foreign country. Unfortunately, these productive manufacturing facilities have mostly shut down since Hurricane Maria hit land nearly four months ago, and the plants that are in operation continue to rely on generators.

Three of the affected manufacturing plants are home to Baxter, one of the most significant suppliers of IV bags. All three of Baxter’s plants on the island were forced to stall manufacturing. While two stations are now up and running on generators, the other remains closed.

According to the New York Times, about 10% of the drugs that Americans consume every day are made in Puerto Rico. While the island continues to recover from the devastating hurricane, medical professionals on the mainland should expect low supply, back orders, and price increases.

Unfortunately, these drug shortages could affect Accutome by Keeler and its customers. Ophthalmology offices should be aware of this backup and prepare accordingly. These professionals should expect Accutome and other providers to be out of certain products like morphine, IV solutions, mesh, surgical scalpels, and more. While the provider works hard to secure these products for customers.

The FDA is working with the manufacturers in Puerto Rico to get production back on track. The agency is currently monitoring a total of 90 products in hopes of stopping shortages before they become critical. The administration is also working with Puerto Rico to get manufacturing back on track.

“We continue to work closely with federal and Puerto Rican authorities to address the needs of manufacturers on the island for power and other resources. … Mitigating medical product shortages will require a sustained effort by the industry, the agency, and other partners as we work with manufacturers to return to production levels that adequately meet the needs of patients,” FDA Commissioner Scott Gottlieb, MD, said in a statement.

Thanks to generous tax incentives, Puerto Rico is home to many big-name manufacturers such as Johnson & Johnson, Pfizer, and Abbott Medical Optics. However, because only about half of these manufacturers are producing right now, medical professionals across the United States are destined to feel the shortage.

Since 2014, the FDA has been monitoring Puerto Rico for potential drug shortages. But Hurricane Maria turned a potential problem into a significant and immediate emergency. This shortage has made it difficult for cancer patients to receive proper care because Baxter makes the saline bags used for treatments. Furthermore, care of premature babies has been placed in jeopardy due to the shortage.

Accutome by Keeler is in its fourth decade of operation and will not allow this hurricane to end its reputation as a leader in the ophthalmic industry. With superior customer service, quality, and innovation, the company will continue to serve its customers through this crisis. Customers should feel free to contact their representatives with any questions they may have.

Accutome by Keeler stands with the people of Puerto Rico, its customers, and its commitment to service. While Hurricane Maria may have disrupted supplies, customers will not see a disruption in the service they have come to expect.

Read more at accutome.com

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Healthcare expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tempus AI's $1.7B Personalis deal leads a surge in health-tech M&A that is already reshaping vendor choices for health system operators

Tempus AI's $1.7B Personalis deal leads a surge in health-tech M&A that is already reshaping vendor choices for health system operators

Digital health mergers and acquisitions (M&A) along with venture capital (VC) activities are rapidly increasing. Tempus AI's $1.7 billion acquisition of Personalis is part of a larger trend that is influencing health system operators’ selection of vendors. With $7.4 billion in funding during the first half of 2026, the health-tech industry is undergoing significant transformation.

  • 01Tempus AI acquired Personalis for $1.7 billion.
  • 02Health-tech received $7.4 billion in funding in the first half of 2026.
  • 03M&A activities are influencing vendor choices for health system operators.

Jul 30, 2026

Digital health AI investment hits $7.4B in H1 2026 as CMS, hospitals, and startups all accelerate adoption

Digital health AI investment hits $7.4B in H1 2026 as CMS, hospitals, and startups all accelerate adoption

In the first half of 2026, digital health AI investments reached $7.4 billion as organizations like CMS, hospitals, and startups increased their adoption of AI. Significant moves include the establishment of a new CMS technology office and a $1.7 billion acquisition in cancer technology. These developments mark an enterprise-level commitment to advancing AI in healthcare.

  • 01Digital health AI investments reached $7.4 billion in H1 2026.
  • 02The CMS established a new technology office to advance healthcare AI.
  • 03A major acquisition in cancer technology totaled $1.7 billion.

Jul 30, 2026

Sensor networks and AI push structural health monitoring toward a $8.6 billion market by 2035

Sensor networks and AI push structural health monitoring toward a $8.6 billion market by 2035

The global structural health monitoring (SHM) market is projected to surpass $8.6 billion by 2035. This growth is fueled by the integration of AI analytics, wireless sensor technologies, and the necessity to address aging infrastructure. The expansion reflects a widespread adoption of these technologies in various sectors.

  • 01The SHM market is expected to exceed $8.6 billion by 2035.
  • 02Advancements in AI-powered analytics and wireless sensors are key drivers of market growth.
  • 03Aging infrastructure is creating a demand for enhanced structural health monitoring solutions.

Jul 24, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512